CK Life Sciences rises most in 4 months on advancing cancer vaccine development

CK Life Sciences Intl (Holdings)

11/03/2026 05:46

** Shares of CK Life Sciences 0775.HK rise 3.8% to HK$0.81, their biggest intraday pct gain since November 13

** Stock touches its highest point since March 5, rising for a second session

** The pharmaceutical products developer announces the establishment of Sequencio Therapeutics Co Ltd to consolidate the company's therapeutic cancer vaccine research and development portfolio and focus on the emerging class of cancer immunotherapy

** Sequencio' preclinical portfolio includes the company's investigational cancer vaccines targeting Trophoblast Cell Surface Antigen 2 and vaccine candidates targeting Preferentially Expressed Antigen in Melanoma, among others

** YTD, stock down 2.4%, while Hang Seng Biotech Index .HSBIO up 2.8%

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))